Your browser doesn't support javascript.
loading
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al.
D'Silva, Kristin M; Serling-Boyd, Naomi; Wallwork, Rachel; Hsu, Tiffany Y-T; Sparks, Jeffrey A; Wallace, Zachary Scott.
Affiliation
  • D'Silva KM; Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Serling-Boyd N; Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Wallwork R; Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Hsu TY; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Sparks JA; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Wallace ZS; Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA zswallace@partners.org.
Ann Rheum Dis ; 81(8): e135, 2022 08.
Article in En | MEDLINE | ID: mdl-32660976
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / COVID-19 Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rheumatic Diseases / Antirheumatic Agents / COVID-19 Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Rheum Dis Year: 2022 Type: Article Affiliation country: United States